A detailed history of Wilbanks Smith & Thomas Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wilbanks Smith & Thomas Asset Management LLC holds 2,930 shares of VRTX stock, worth $1.35 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,930
Previous 2,926 0.14%
Holding current value
$1.35 Million
Previous $1.19 Million 2.86%
% of portfolio
0.03%
Previous 0.04%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$407.69 - $446.08 $1,630 - $1,784
4 Added 0.14%
2,930 $1.22 Million
Q3 2023

Nov 06, 2023

BUY
$338.18 - $362.46 $7,439 - $7,974
22 Added 0.76%
2,926 $1.02 Million
Q2 2023

Aug 08, 2023

SELL
$314.42 - $351.91 $15,721 - $17,595
-50 Reduced 1.69%
2,904 $1.02 Million
Q1 2023

May 05, 2023

SELL
$283.23 - $323.1 $1,699 - $1,938
-6 Reduced 0.2%
2,954 $930,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $857 - $964
-3 Reduced 0.1%
2,960 $854,000
Q3 2022

Oct 31, 2022

SELL
$273.83 - $305.53 $3,559 - $3,971
-13 Reduced 0.44%
2,963 $858,000
Q2 2022

Aug 03, 2022

BUY
$234.96 - $292.55 $5,404 - $6,728
23 Added 0.78%
2,976 $839,000
Q1 2022

May 05, 2022

BUY
$221.42 - $260.97 $13,285 - $15,658
60 Added 2.07%
2,953 $795,000
Q4 2021

Feb 08, 2022

SELL
$177.01 - $223.45 $3,363 - $4,245
-19 Reduced 0.65%
2,893 $635,000
Q3 2021

Nov 04, 2021

SELL
$181.39 - $202.99 $3,265 - $3,653
-18 Reduced 0.61%
2,912 $528,000
Q2 2021

Aug 04, 2021

SELL
$187.49 - $221.1 $25,123 - $29,627
-134 Reduced 4.37%
2,930 $591,000
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $25,049 - $29,198
-121 Reduced 3.8%
3,064 $658,000
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $3,519 - $4,693
17 Added 0.54%
3,185 $753,000
Q2 2020

Jul 31, 2020

BUY
$225.48 - $295.8 $24,802 - $32,538
110 Added 3.6%
3,168 $920,000
Q1 2020

May 06, 2020

BUY
$199.77 - $247.81 $39,354 - $48,818
197 Added 6.89%
3,058 $728,000
Q2 2018

Aug 08, 2018

BUY
$145.72 - $169.96 $6,703 - $7,818
46 Added 1.63%
2,861 $486,000
Q4 2017

Feb 07, 2018

SELL
$137.28 - $155.55 $84,839 - $96,129
-618 Reduced 18.0%
2,815 $422,000
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $91,544 - $100,264
618 Added 21.95%
3,433 $522,000
Q2 2017

Aug 15, 2017

BUY
N/A
2,815
2,815 $363,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wilbanks Smith & Thomas Asset Management LLC Portfolio

Follow Wilbanks Smith & Thomas Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.